Equity Story

curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications. These are materials mimicking biological structures which can be entirely absorbed and remodeled by the body.

In its almost 30 year history curasan has been granted nine patents and has filed ten additional patent applications. The core brands of curasan include the top-quality products Ceracell®, Osbone®, Osseolive® and the flagship product CERASORB®. curasan’s scientific documentation of clinical success in the market for synthetic bone replacement materials is unsurpassed. Today, the phase purity of the beta-tricalcium phosphate used in CERASORB® is considered the global reference standard in the market. The numerous product versions available, from granules and pastes to moldable foams and molded implants, give surgeons and implantologists optimal flexibility depending on the medical indication.

Change of management in 2014 has started a new era in the company’s development. Today, curasan is focusing on the marketing of a selection of its own highly profitable products using a distribution network of more than 80 partners in over 50 countries. The goal is to reach sustainable growth and lasting profitability. The dental segment is planned to be further extended; however, the future for curasan and its products lies in the orthopedics market, which consists of two thirds of the total market for bone graft materials worldwide. Priority regions are the US, by far the biggest international market, as well as China with its above-average growth potentials.

curasan overview